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Abstract
Background: The development of cellular therapies to treat muscle wastage with disease or age is paramount.
Resident muscle satellite cells are not currently regarded as a viable cell source due to their limited migration and
growth capability ex vivo. This study investigated the potential of muscle-derived PW1+/Pax7– interstitial progenitor
cells (PICs) as a source of tissue-specific stem/progenitor cells with stem cell properties and multipotency.
Methods: Sca-1+/PW1+ PICs were identified on tissue sections from hind limb muscle of 21-day-old mice, isolated
by magnetic-activated cell sorting (MACS) technology and their phenotype and characteristics assessed over time
in culture. Green fluorescent protein (GFP)-labelled PICs were used to determine multipotency in vivo in a tumour
formation assay.
Results: Isolated PICs expressed markers of pluripotency (Oct3/4, Sox2, and Nanog), were clonogenic, and self-
renewing with >60 population doublings, and a population doubling time of 15.8 ± 2.9 h. PICs demonstrated an
ability to generate both striated and smooth muscle, whilst also displaying the potential to differentiate into cell
types of the three germ layers both in vitro and in vivo. Moreover, PICs did not form tumours in vivo.
Conclusion: These findings open new avenues for a variety of solid tissue engineering and regeneration approaches,
utilising a single multipotent stem cell type isolated from an easily accessible source such as skeletal muscle.
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Background
Muscular dystrophy results in progressive skeletal
muscle weakness and wastage [1] due to defects and/or
the inability to make the protein dystrophin and other
associated protein complexes. There are approximately
70,000 babies, children, and adults in the UK suffering
from some form of muscular disease, with 12.6% of these
being dystrophic disorders such as Duchenne’s muscular
dystrophy (DMD). DMD is a progressive muscle wasting
disease which affects approximately 1 in 3500 boys and
often results in death due to respiratory failure before
25 years of age [2]. Current treatments include physio-
therapy and corticosteroids to improve muscle strength,
along with surgery to correct associated spinal curvature;
these treatments, however, are not a cure and only serve
to manage the condition. Muscle degeneration also oc-
curs with ageing (termed sarcopenia) where the body’s
ability to replace muscle fibres decreases resulting in a
progressive loss of muscle mass with a reduction in the
cross-sectional area of muscle fibres [3]. Indeed, 20% of
all 60–70 year olds have sarcopenia, and this figure rises
to 50% in those over 75 years [4].
Stem cell regenerative cellular therapies may eventu-
ally provide effective treatments for the restoration of
skeletal muscle weakness and wastage. In conditions
such as muscular dystrophy or sarcopenia, where the
condition affects a large area and important tissue of the
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human body, it is imperative that we develop cellular
therapies that can repair damage and restore function in
situ [5]. Skeletal muscle harbours resident progenitor
satellite cells which are capable of myogenic differenti-
ation in vitro and in vivo and extensively contribute to
new muscle fibre formation [6]. However, transplanted
satellite cells have limited migration capacity with an in-
ability to cross the endothelial wall [7, 8]. Satellite cells
that have undergone culture ex vivo also have decreased
proliferative capacity and a reduction in myofibre pro-
duction when transplanted in vivo [9, 10]; therefore, sat-
ellite cells are not currently regarded as a viable source
for transplantation regenerative cell therapies.
Since the first discovery of satellite cells 50 years ago
[11], a variety of other muscle-derived stem cells have
been identified. These include vessel-associated cells
such as mesoangioblasts [12] and pericytes [13, 14],
alongside interstitial cells such as side population cells
[15], fibro/adipogenic progenitors (FAPs) [16], and
PW1-positive interstitial cells (PICs) [17]. PW1+/Pax7–
PICs are bi-potent, efficiently contributing to smooth
and skeletal muscle regeneration in vivo, whilst also gen-
erating satellite cells and replenishing the PIC popula-
tion [17]. PICs have also been described by us in the
hind limb muscle of pigs [18]. PW1 (also known as pa-
ternally expressed gene 3, or peg3) is a nuclear protein
expressed in both PICs and quiescent satellite cells, al-
though it is not known if activated satellite cells con-
tinue to express PW1 [17, 18]. PICs and satellite cells
are distinguishable by both location and molecular
markers; satellite cells express Pax7 and are located
under the basal lamina [11], whilst PICs do not express
Pax7 and are located in the interstitium [17, 18]. Murine
PICs are also positive for stem cell antigen (Sca)-1,
whilst both satellite cells and PICs are negative for
CD45. Approximately 15% of myoblasts also express
PW1, most commonly during the final stages of mitosis
[19]. Transcriptome and gene ontology analyses of PICs
and satellite cells from 1-week-old mice show that both
cell types have distinct transcriptome signatures, with
satellite cell-specific genes belonging primarily to the
skeletal muscle lineage, whilst PICs express genes from
multiple cell fates [20]. Utilising PW1-reporter trans-
genic mice, PW1 expression has been described in mul-
tiple adult stem cell niches throughout the body
including the gut, skin, central nervous system (CNS),
and early haematopoietic stem cells [21]. Therefore, it
has been implicated as a possible marker for stem/pro-
genitor cell populations throughout the adult mamma-
lian body.
One of the bottlenecks with the translation of stem
cell therapy to the clinic is the generation of enough
stem/progenitor cells that maintain their phenotype and
differentiation potential to produce efficacious results in
vivo. Results of recent clinical trials where bone
marrow-derived cells are transplanted after myocardial
infarction (MI) have been disappointing [22, 23]. This is
due to low cell survival and retention, a hostile host en-
vironment, and subsequent restriction of cell prolifera-
tion, integration, and differentiation [24–26]. The
majority of the trials performed to date have utilised
freshly isolated unfractionated bone marrow to avoid
introducing variability associated with expanding these
cells in vitro [27].
Stem cells are maintained in a quiescent state until ac-
tivated by injury or another stimulus [28, 29]. Therefore,
a freshly isolated stem cell is quiescent and, unless acti-
vated in vitro, will not exit from G0 and upon trans-
plantation, coupled with the hostile host environment,
will be more prone to death. Therefore, to maximise
their survival and regenerative potential, stem/progeni-
tor cells need to be propagated in vitro to large numbers
before transplantation in vivo. Therefore, the in vitro
propagation and characterisation of the cells over cul-
ture time needs to be optimised and validated. Moreover,
the use of a clonogenic cell population, which is a
homogeneous and uniform therapeutic product, would
mean patients receive the same dose of identical cells
and the only independent variable would be the patients
themselves. Here we assessed whether PW1+/Pax7– PICs
behave as tissue-specific stem/progenitor cells by exhi-
biting properties of clonogenicity, self-renewal, and
multi-potency in vitro and in vivo.
Methods
Animals
All experimental procedures were performed in accord-
ance with the British Home Office Animals (Scientific
Procedures) Act 1986 by appropriately qualified staff
and approved by the institutional animal welfare and
ethical review board of King’s College London. C57BL/6
mice were sacrificed at 3 days (2.6 ± 0.1 g), 10 days (5.4
± 0.2 g), 21 days (7.8 ± 0.4 g), and 2 years (35.7 ± 1.2 g)
of age via CO2 asphyxiation or cervical dislocation.
Immunohistochemistry/immunocytochemistry
Immediately after sacrifice dissected skeletal hind limb
muscle was fixed in formalin for 24 h before tissue pro-
cessing and embedding in paraffin wax blocks. Tissue
sections (5 μm) were cut and mounted on polysine™
microscope slides. Following deparaffinisation, rehydra-
tion, and antigen retrieval, tissue sections were blocked
with 10% donkey serum.
Cells grown on chamber slides were fixed with 4% for-
maldehyde for 20 min at room temperature.
For cytospin preparations, 10,000 cells per spot were
spun down onto polysine™ slides using a Cytospin 4 cen-
trifuge and Shandon EZ double cytofunnels, then fixed
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with Shandon cellfix spray. The fixative was removed
with 95% ethanol for 15 min. For staining of nucleic pro-
teins, cells were permeabilised with 0.1% triton before
cells were blocked with 10% donkey serum in 0.1%
Tween phosphate-buffered saline (PBS).
Primary antibodies were applied for either 1 h at 37 °C
or overnight at 4 °C (See Additional file 1: Table S1 for a
list of antibodies). Relevant secondary antibodies were
applied (1/100 dilution) for 1 h at 37 °C. Nuclei were
counterstained with the DNA binding dye 4,6-diami-
dino-2-phenylindole (DAPI; 1:1000) for 15 min at room
temperature.
All quantification was conducted at × 40 magnification
on a fluorescence microscope (Nikon, E1000M Eclipse)
and representative Z stack micrographs imaged on a
confocal microscope (Zeiss, LSM 710).
Haematoxylin and eosin staining
To visualise different cell types within the tumour, sec-
tions were stained with haematoxylin and eosin to iden-
tify nuclei and cytoplasm respectively.
DAB staining
To determine which tumour cells arose from GFP+ PICs
and were not a result of the embryonic stem cells
(ESCs), paraffin-embedded tumour tissue sections were
prepared and stained for green fluorescent protein (GFP;
Abcam; 1 h at 37 °C) and endogenous peroxidase activ-
ity was blocked using 1 part H2O2 to 3 parts PBS for
15 min at room temperature. Donkey-anti-Rabbit HRP
(Santa Cruz, Texas, USA) was applied for 1 h at 37 °C
and SigmaFast DAB tablets were used to visualise the
GFP.
Cell isolation
Skeletal muscle hind limb from 21-day-old mice was dis-
sected and rinsed in basic buffer (MEM, 2.93 mM
Hepes, 2.05 mM glutamine, 9.99 mM taurine, pH 7.3).
The tissue was minced extensively with scissors and
stirred at 37 °C for 30 min in digestion buffer (basic buf-
fer (as above), 7 mg/ml collagenase II). Following diges-
tion, the preparation was centrifuged at 300 g for 1 min
(brake 3). The supernatant, containing the small cells,
was filtered (40 μM) and the pellet discarded. The cell
suspension was then topped up to 30 ml with incubation
buffer (basic buffer (as above), 0.5% bovine serum albu-
min (BSA), pH 7.3) and spun at 1500 rpm for 7 min
(brake 7) after which the supernatant was discarded and
the pellet re-suspended in 1 ml incubation medium
(PBS, 0.5% BSA, 2 μM EDTA). The small cell population
was then sorted for the PIC cell population using
magnetic-activated cell sorting (MACS) as per standard
protocol (Miltenyi). Briefly, using direct mouse CD45
microbeads (Miltenyi) the CD45+ cells were depleted
from the cell preparation, leaving the CD45– fraction;
from this, the Sca-1+ cells were then enriched using an
indirect (FITC) mouse Sca-1 microbead kit (Miltenyi).
Cell culture
Cells were cultured on 1.5% gelatin coated dishes in
growth medium (45% Dulbecco’s modified Eagle’s medium
(DMEM)/F12 Ham, 1× insulin-transferrin-selenium (ITS),
45% neurobasal medium, 0.5% glutamax, 1× B27, 1× N2,
20 ng/ml epidermal growth factor (EGF), 10 ng/ml basic
fibroblast growth factor (bFGF), 10% embryonic stem cell
qualified fetal bovine serum (ESCQ-FBS), 10 ng/ml leu-
kaemia inhibitory factor (LIF), 1% penicillin/streptomycin,
0.1% fungizone, 0.1% gentamicin). Cultures were incu-
bated at 37 °C in 5% CO2 and passaged 1 in 3 when they
reached ~80% confluency using 0.25% trypsin-EDTA
solution.
Mouse ESCs (gifted from Agi Grigoriadis, Kings
College London) were cultured on 1% gelatin-coated
dishes in ESC growth medium (10% FBS, 1 mM sodium
pyruvate, MEM non-essential amino acids, 50 mM β-
mercaptoethanol, 1000 U/ml GSK-inhibitor, 1000 U/ml
MEK-inhibitor, 1000 U/ml LIF).
Single cell-derived clonal colonies were generated by
serial dilution seeding of one cell per well of a 1.5%
gelatin-coated 96-well tissue culture plate. Clonogenicity
was assessed as a percentage of seeded wells that went
on to form colonies.
Directed differentiation
C9 PICS (P5) were plated at 2 × 104 cells/cm2 in 10-cm2
dishes or four-well glass chamber slides as described
below. Media were changed every 3 days.
Myogenic: 1.5% gelatin-coated dishes for 5 days in
myogenic media; high-glucose (4.5 g/L) DMEM, 2%
horse serum, 1% penicillin/streptomycin.
Endothelial: 10 μg/ml fibronectin-coated dishes for
7 days in endothelial media; DMEM, 10 ng/ml vascu-
lar endothelial growth factor (VEGF), 1% penicillin/
streptomycin.
Hepatic: 10 μg/ml fibronectin-coated dishes for 14 days
in hepatic media; low-glucose DMEM, 25% F12K media,
20 ng/ml hepatocyte growth factor (HGF), 10 ng/ml
oncostatin, 1× ITS, 5 mM nicotinamide, 2.5% FBS, 1%
penicillin/streptomycin.
Neuronal: 1 μg/ml laminin-coated dishes for 14 days
in neuronal medium: low-glucose DMEM, 10% horse
serum, 300 ng/ml retinoic acid.
GFP transduction
C9 PICs (P10) were transduced with the construct for
GFP via lentiviral transduction; 106 293 T cells at 70%
confluency were treated with 5 μg Delta 8.9 plasmid,
10 μg GFP plasmid, 2 μg VSV-g plasmid (pre-prepared
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plasmids gifted from Daniele Torella, Magna Graecia
University, Italy), and 30 μl Lipofectamine2000 in 6 ml
of OptiMEM-I for 4 h. A further 5 ml of OptiMEM-I
containing 10% FBS and 1% penicillin/streptomycin was
then added. After 24 h the media was changed for nor-
mal 293 T growth media and left for a further 24 h, after
which the lentiviral supernatant was collected. PICs were
transduced for 24 h using a 1: 5 ratio of lentiviral super-
natant:PIC media containing 8 μg/ml polybrene. The
transduction efficiency was checked by flow cytometry.
Tumourigenicity assay
Twelve-week-old C57BL/6 were anaesthetised via inhal-
ation of isoflurane and immediately given antibiotics
(0.5 ml Betamox LA) and pain relief (5 mg/kg Carprieve)
subcutaneously and Viscotears used on the eyes to
prevent drying. Animals were placed on a heat mat
throughout surgery and recovery. Hair was removed
prior to incision using clippers and Nair™ hair removal
cream (3 min) before disinfection with Hibiscrub. A
small (~10 mm) incision was made midline on the
mouse right hand side just under the ribcage, followed
by a slightly smaller incision (~7 mm) in the peritoneum
directly underneath. The kidney was then gently exposed
using small non-toothed forceps to hold it in place. A
small incision was made to the kidney capsule using a
27 gauge needle without piercing the kidney itself. The
kidney capsule was kept moist with PBS containing
0.05% gentamicin throughout. A small space was then
made between the kidney and its capsule using a fine
pipette tip containing the cell mix. The cell mix (1 × 106
cells in 10 μl of 70% matrigel) was deposited slowly,
forming a gel-like ball as the matrigel solidified, and the
entry site cauterized to prevent leakage. The peritoneum
and skin were individually closed using 5-0 Vicryl su-
tures and the animal allowed to recover. Ten out of 12
animals that were operated on survived (one did not re-
cover, one died 24 h post-surgery). Animals were sacri-
ficed 4 weeks post-surgery and assessed for tumour
formation.
Flow cytometry
Cells were blocked with 10% donkey serum in incuba-
tion medium (PBS, 0.5% BSA, 2 μM EDTA) immediately
before incubation with the primary antibody. For nuclear
expression of PW1, cells were permeabilised with BD
fixation/permeabilisation kit as per the manufacturer’s
instructions prior to the blocking step. Flow cytometry
was conducted on a BD FACS Calibur and 10,000 events
recorded for each analysis. Results were plotted and ana-
lysed using Flowing Software (Turku Centre for Biotech-
nology). See Additional file 2 (Table S2) for antibodies
and controls used.
Quantitative reverse-transcription polymerase chain
reaction (qRT-PCR)
Total mRNA was obtained from cell pellets using the
QIAshredders and RNeasy mini kit (Qiagen). Final
mRNA concentration (ng/μl) and quality (260/280 and
260/230 ratio) of the resulting flow though was mea-
sured using a Nanodrop 2000.
cDNA was synthesised via reverse transcription, using
a Taqman reverse transcription (RT) kit (Life technolo-
gies). qRT-PCR was performed on a Biorad i-cycler with
a MyIQ detection system, using IQ SYBR Green super-
mix, 1 μl of template cDNA, and 500nM of forward and
reverse primers with the following program:
1. 95 °C – 5 min
2. 40 cycles of:
a. 95 °C – 15 s
b. 60 °C – 30 s
c. 72 °C – 30 s
Florescence was detected as the end of each amplifica-
tion cycle (step 2c).
Melt curve analysis was performed on all reactions at
0.5 °C increments between 55 and 95 °C to detect any
genomic DNA contamination, primer dimers, and/or
non-specific amplification. Data were analysed using
BioRad IQ software, and the transcript copy number es-
timated by normalising results to the housekeeping gene
(HKG) GAPDH, using the following equation where Ct
= cycle threshold.
Copy number of target = 2500*1.93^(HKi – target Ct)
All primers were designed using NCBI Primer-BLAST
software, with melting temperatures of 60 °C and primer
lengths of ~20. All reactions were performed in triplicate.
See Additional file 3 (Table S3) for primer sequences.
Statistical analysis
Data are presented as mean ± SD. Significance between
two groups was determined using an independent t test.
For analysis of more than two groups, one-way analysis
of variance (ANOVA) was performed with the Tukey
post-hoc method to locate the differences. Significance
was reported at p < 0.05.
Results
Abundance of PW1+ PICs and satellite cells decreases into
old age
Expression of PW1+ PICs and satellite cells were assessed
by immunohistochemistry on hind limb skeletal muscle
cross-sections at 3, 10, and 21 days and 2 years. PW1+
cells were classified as being PICs located within the inter-
stitial spaces, or satellite cells under the basal lamina,
when counterstained with laminin (Additional file 4:
Figure S1). To account for activated satellite cells within
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the interstitial spaces, Pax7 staining was employed; how-
ever no interstitial cells expressing both Pax7 and PW1
were found. A small fraction of interstitial PW1+/Pax7–
cells may be myoblasts in final stage mitosis.
At 3 days of age, ~9% of total nuclei were positive for
PW1, with ~5% being PW1+ PICs and ~4% being PW1+
satellite cells. The abundance of PW1+ cells decreased
with age to less than ~1.5% of total nuclei in 2-year-old
animals. Most of these PW1+ cells (~1%) were identified
as quiescent satellite cells (Additional file 4: Figure S1).
Similarly, the number of PW1 nuclei per muscle fibre
decreased with age from 1/3 fibres at 3 days to 1/31 fi-
bres at 2 years. The decline in PW1+ PICs from 3 to
21 days was about 50%, going from ~5% of total nuclei
at 3 days to 2.5% at 21 days (Additional file 4: Figure
S1). In young mice between 3 and 21 days, PICs repre-
sented ~57% of all PW1+ cells, whilst this dropped sig-
nificantly to ~30% in aged animals. In young mice
between 3 and 21 days, satellite cells represented ~43%
of PW1+ cells, but by 2 years this had increased to ~70%
(Additional file 4: Figure S1). Therefore, the number of
PW1+ PICs and PW1+ satellite cells decreases with age,
yet the proportion of PW1+ quiescent satellite cells to
PW1+ PICs increases, which suggests PW1+ PICs are de-
clining at a faster rate with age. This could be because
PW1+ PICs are taking up position as satellite cells to com-
pensate for the decrease in satellite cells with age [30].
PW1+ PICs express stemness markers and can be purified
and propagated in vitro
Murine PICs are enriched in the Sca-1-positive (Sca-1+)
CD45-negative (CD45–) fraction of muscle-derived cells,
whereas the satellite cells reside in the Sca-1-negative
fraction [17]. To isolate a purified population of young
adult PICs we enzymatically digested murine hind limb
muscle obtained from both legs of 21-day-old mice and,
through MACS technology (Miltenyi), sorted the muscle-
derived cells for the CD45-negative followed by the Sca-1-
positive cell fraction. Approximately 800,000 CD45–/Sca-
1+ PICs were obtained per mouse.
We tested two different cell media for the propagation
of CD45–/Sca-1+ PICs; 15,000/cm2 CD45–/Sca-1+ PICs
were plated in either complete skeletal muscle media
purchased from Promocell or a defined stem/progenitor
cell growth media, optimised and used by our laboratory
[31] (Fig. 1a and b). After 6 days, cells cultured in Pro-
mocell media did not expand and showed a >50% de-
crease in number and appeared large and flattened
(Fig. 1a and c). In contrast, CD45–/Sca-1+ PICs plated in
our stem/progenitor cell growth media contained a
number of small round bright cells (Fig. 1b) and had in-
creased 10-fold in number to 150,000/cm2 (Fig. 1c). By
passage 3, the number of small round bright cells with a
very high nucleus to cytoplasmic ratio, which adhered to
the culture dish, had visibly increased (Fig. 1d). This in-
crease in small rounded bright cells was maintained for
the duration of time in culture (20 passages) and these
small cells detached quickly when trypsinised with very
little cell death occurring at each passage. In contrast,
the cells maintained in Promocell media arrested
growth, did not show any small rounded bright cells,
and did not get past P0; when trypsinised, the cells did
not detach from the dish.
To determine whether our stem/progenitor cell growth
media purifies for a stem/progenitor cell population we
characterised CD45–/Sca-1+ PICs for the markers of stem-
ness and pluripotency (Sox2, Oct3/4 and Nanog) at P0
(freshly isolated) and P3. Freshly isolated cells expressed
Sox2 (5%), Oct3/4 (18%), and Nanog (18%); however, by
P3 all (>98%) of the cells were positive for Sox-2, Oct3/4,
and Nanog (Fig. 1e). In addition, gene transcription was
assessed by qRT-PCR and compared to that of murine
ESCs. As expected, CD45–/Sca-1+ PICs expressed tran-
scripts for PW1, Sca-1, and CD34, whilst being negative
for CD45 (transcript copy number < 1). CD45–/Sca-1+
PICs expressed transcripts for Sox2, Oct3/4, and Nanog,
although all were lower than levels present in ESCs
(Fig. 1f).
PW1+ PICs maintain a PIC phenotype over culture time
To ensure that propagation in culture did not change
the phenotype of CD45–/Sca-1+ PICs, we analysed
CD45–/Sca-1+ PICs at P3 for an array of markers previ-
ously described in PIC populations using immunocyto-
chemistry and flow cytometry analysis. In agreement
with a PIC phenotype, CD45–/Sca-1+ cells at P3 were
confirmed as being CD45–, Pax-7–, Sca-1+, and PW1+
(Fig. 2a). Flow cytometry confirmed these data, and also
showed that PICs did not express the endothelial
markers CD31 or CD146, nor the pericyte markers NG2
and PDGFRβ (≤2%), but did express PDGFRα (19%),
CD34 (51%), and CXCR4 (59%) (Fig. 2b). A low percent-
age (8%) of CD45–/Sca-1+ cells also expressed the stem
cell factor receptor, c-kit (Fig. 2b).
PW1+ PICs are clonogenic and self-renewing
PICs that had been propagated to passage 3 were depos-
ited as a single cell/well by serial dilution into 96-well
cloning plates. After 12 days the number of colonies de-
rived from each well was quantified; 34 ± 11% of single
PICs formed clonal colony populations of small rounded
cells, which formed aggregates at high density (Fig. 3a).
Seven clones were picked for further analysis. The clones
all expressed high levels of PW1 and Sca-1, maintaining
a PIC phenotype (Additional file 5: Figure S2). The
clones also expressed comparable transcript levels of
PW1, Sca-1, CD34, Oct3/4, and Nanog compared to
bulk cultured PICs when analysed by qRT-PCR
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Fig. 1 (See legend on next page.)
Cottle et al. Stem Cell Research & Therapy  (2017) 8:158 Page 6 of 16
(Additional file 6: Figure S3). However, only one clone
(C9) maintained expression of Sox-2 (Additional file 6:
Figure S3). C9 was selected for further characterisation
and propagated for over 20 passages, maintaining its
morphology (Fig. 3b), and expression of Sca-1 and PW1
at passages 1, 10, and 20 (Fig. 3c and d). Flow cytometry
analysis for surface markers previously screened for in
bulk PICs was conducted at P2 and P20 on C9. When
compared to bulk PICs, C9 PICs had increased expres-
sion of CD34 (~6% increase) and CXCR4 (~20% in-
crease), whilst C9 PICs no longer expressed PDGFRα
(Additional file 7: Figure S4). There were no notable
changes of more than 5% between P2 and P20 for any of
the surface markers, showing that C9 maintained a
(See figure on previous page.)
Fig. 1 Growth and phenotype of CD45–/Sca-1+ PICs. a,b Representative light microscope images of CD45–/Sca-1+ positive interstitial cells (PICs)
isolated from 21-day-old mice after 6 days in culture with Promocell media (a) or growth media (b). Scale bars = 200 μm. c Cell count at initial
plating (D0) and after 6 days (D6) of culture in Promocell or PIC growth media (n = 1 culture dish). d Representative light microscope image of
CD45–/Sca1+ PICs cultured to passage 3 (P3) in growth media. Scale bar = 200 μm. e Representative confocal micrograph of freshly isolated and
cultured (P3) PICs showing expression of the pluripotency markers Sox2, Oct3/4, and Nanog. Quantification of positive cells is percentage of total
cells counted. Scale bar = 50 μm. f qRT-PCR transcript analysis for PICs at P3 and mouse embryonic stem cells (ESCs). Bars represent the mean
relative expression normalised to GAPDH. Error bars represent the standard deviation of the mean; n = 3
Fig. 2 PICs retain their phenotype after three culture passages. a Representative confocal micrograph showing CD45–/Sca-1+ PICs at P3 are negative
for CD45 and Pax-7 and positive for Sca-1 and PW1. Scale bar = 50 μm. b Flow cytometric analysis of CD45–/Sca-1+ PICs at P3 for the cell surface
markers Sca-1, CD45, CD34, PDGFRα, CD31, c-kit, PDGFRβ, CD146, NG2, and CXCR4 and the nuclear markers Pax7 and PW1. Grey histogram represents
the isotype control and the green histogram represents protein of interest in all histograms
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stable phenotype over 20 passages (Additional file 7:
Figure S4). Furthermore, C9 maintained a stable popula-
tion doubling time of 16 ± 3 h over 20 passages, which
equated to ~64 total population doublings over 20 pas-
sages (Fig. 3e). qRT-PCR analysis of C9 at P1, P10, and
P20 showed a comparable transcript profile at each pas-
sage, with only the levels of Sox-2 markedly decreasing
over culture time (Fig. 3f ).
C9 PICs deposited as a single cell in a 96-well plate
produced single-cell derived sub-clones with an effi-
ciency of 91 ± 2%, which was maintained when clonal ef-
ficiency was assessed at every fifth sub-cloning passage
until passage 20 (Fig. 4a and b). PICs grown as bulk
cells, their single-cell derived clones, and the single cell-
derived sub-clones all maintained high levels of Sca-1
and PW1 expression when assessed by flow cytometry
(Fig. 4c and d; Additional file 8: Figure S5 and
Additional file 9: Figure S6).
qRT-PCR analysis revealed that, although the ex-
pression of PW1, CD34, and Sca-1 was consistent
between bulk cells, clones, and sub-clones, the expres-
sion of pluripotent markers Oct3/4, Sox-2, and Nanog
gradually decreased (Fig. 4e), emanating into the sub-
clones of C9 being negative for Sox-2, Oct3/4 and
Fig. 3 PICs are clonogenic and clones can be maintained over long-term culture. a Representative light microscope image of a single PIC in a
well of a 96-well plate (scale bar = 100 μm), and subsequent clonal population after 12 days of culture (scale bar = 500 μm). b Representative light
microscope images of C9 PIC morphology at passage (P)1, P10, and P20. Scale bar = 200 μm. c,d Flow cytometric analysis of C9 PICs for Sca-1 (c)
and PW1 (d) at P2, P10, and P20. e Population doubling time of C9 PICs over 20 passages. Data are mean ± SD, n = 3. f qRT-PCR transcript analysis
of C9 PICs at P1, P10, and P20. Bars represent the mean relative expression normalised to GAPDH. Error bars represent the standard deviation of
the mean; n = 3
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markedly reduced for Nanog (Additional file 9: Figure
S6). As the expression of Oct3/4, Sox-2, and Nanog
was >98% in bulk cells (Fig. 1e), one would expect that
a single cell-derived clone from bulk cells would be
positive for pluripotent markers. Clones maintained
positivity for Oct3/4, Sox-2, and Nanog, and yet the
levels were decreased compared to bulk PICs (Fig. 4e;
Additional file 9: Figure S6). Therefore, the expression
levels of the pluripotent transcripts must have
decreased in the clonal and sub-clonal population over
culture time.
PW1+ PICs and their clonal derivatives are bi-potent,
differentiating into twitching myotubes and smooth
muscle cells
When placed in myogenic differentiation media, bulk
PICs, clonal PICs, and sub-clone PICs all formed myo-
tubes, which were found to beat or twitch after 4 days of
Fig. 4 PIC sub-clone characterisation. a Representative light microscope images of bulk cultured, clonal, and sub-clonal PICs. b Sub-cloning
efficiency of C9 PICs at every fifth passage up to passage (P)20. Data are mean ± SD; n = 3. Sca-1 (c) and PW1 (d) expression quantified by flow
cytometry for bulk, clonal, and sub-clonal PICs. Data are mean ± SD; bulk, n = 1; clones, n = 7; sub-clones, n = 3. e qRT-PCR transcript analysis of
bulk, clones, and sub-clones. Bars represent the mean relative expression normalised to GAPDH. Error bars represent the standard deviation of the
mean; n = 3
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differentiation (Fig. 5a–c). However, efficiency of myo-
tube formation and twitching was more pronounced in
clonal and sub-clonal PICs than in bulk PICs (Fig. 5a–c;
Additional file 10: Video). Differentiated cells were fixed
and stained for MHC and α-sarcomeric actin to show
striated muscle differentiation, and smooth muscle actin
(SMA) and calponin to show smooth muscle differenti-
ation of PICs (Fig. 5d). Bulk, clonal, and sub-clonal PICs
showed increased differentiation into striated muscle
(80% of cells expressed myosin heavy chain (MHC) and
α-sarcomeric actin) compared to smooth muscle (~20%
of cells expressed SMA and calponin) (Fig. 5e). Similar
increases were also seen in the transcripts for striated
and smooth muscle differentiation (Fig. 5f and g). These
findings show that, in this case, single-cell derived clon-
ing selects for a myogenic population of PICs.
PW1+ PICs have a broad developmental plasticity
PICs are bi-potent, differentiating into smooth muscle
cells and skeletal muscle fibres, which are cell types that
Fig. 5 PICs are bi-potent. a–c Representative light microscope images of skeletal myogenic differentiated bulk (a), clonal (b), and sub-clonal (c)
PICs. Scale bar = 200 μm. d Representative confocal micrograph showing differentiation of C9 PICs into skeletal muscle and smooth muscle
lineage positive cells (myosin heavy chain (MHC), α-sarcomeric actin (α-sarc), smooth muscle actin (SMA), and calponin, all red). Scale bar = 50 μm.
e Quantification of differentiated cells in bulk, clonal, and sub-clonal PIC populations. Data are mean ± SD; n = 3. (f) qRT-PCR transcript analysis for
muscle markers MHC, α-sarc, SMA, and desmin after 5 days of directed myogenic differentiation of bulk, clonal, and sub-clonal PICs. Bars represent
the mean relative expression normalised to GAPDH. Error bars represent the standard deviation of the mean; n = 3. g Fold-change in transcript
copy number for MHC, α-sarc, SMA, and desmin over undifferentiated PICs. Data are mean ± SD; n = 3
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originate from the mesoderm layer. The ability of PICs
to differentiate the trans-germ layer into cell types from
the other two germ layers, the endoderm and ectoderm,
has not yet been described. As PICs express the pluripo-
tency markers Oct3/4, Nanog, and Sox2 (Fig. 1e and f)
we sought to assess their trans-germ layer differentiation
potential and potency in vitro and in vivo.
First, we showed that PW1+ PICs differentiate into
non-myogenic cells from the mesoderm layer, such as
endothelial cells (Fig. 6a). To demonstrate cross-
lineage differentiation into cell types of the endoderm
lineage, C9 PICs were placed in hepatic differentiation
media for 14 days, after which they displayed a change
in morphology, and expressed proteins for cytokeratins
18 and 19 and albumin (Fig. 6b–d). Neurogenic differ-
entiation was selected to determine the differentiation
potential of PICs into cell types of the ectoderm
lineage. After 14 days of directed neurogenic differen-
tiation, a small number of cells became spindle shaped
with dendritic projections as seen in neuronal cell
types and expressed proteins for choline acetyltransfer-
ase (ChAT), glial fibrillary acidic protein (GFAP), class
III beta tubulin (β-3-tubulin), and gamma-enolase
(ENO2) (Fig. 6e–h). Differentiated PICs also showed
increased transcript expression for each lineage com-
pared to undifferentiated PICs (Additional file 11:
Figure S7).
Next, we determined the trans-germ layer differenti-
ation potential and potency of PICs in vivo utilising the
teratoma assay where PICs were transplanted under the
kidney capsule alongside ESCs. To distinguish between
cells that arose from ESCs or PICs, C9 PICs (P10) were
transduced with a GFP construct prior to injection.
Post-transduction, GFP+ PICs demonstrated normal PIC
morphology and their GFP expression was ~99%, con-
firmed at P2 post-transduction (Additional file 12: Figure
S8). GFP+ PICs were propagated for 8 passages to obtain
enough cells to perform the assay. Mouse ESCs were
cultured feeder-free prior to transplantation to prevent
MEF contamination.
Mice injected with PBS (no cells) or those injected
with GFP+ PICs only did not form tumours, demonstrat-
ing that PICs are not tumorigenic (Additional file 12:
Figure S8). In contrast, mice injected with ESCs, and
those injected with a 50/50 mix of ESCs and GFP+ PICs,
displayed hair loss and tumour formation, which con-
tained a variety of cell types with different morphologies
(Additional file 12: Figure S8). Indeed, mononuclear PIC
derivatives, detected with anti-GFP antibody, were seen
as mesodermal, ectodermal, and endodermal lineages
(Fig. 6i), supporting a broad plasticity of PICs. However,
the majority of GFP+ cells expressed mesodermal
markers (desmin-positive, SMA-positive), reflecting PIC
bi-potency in vivo (Fig. 6i).
Discussion
The main findings that emanate from this study are: 1)
PICs can be successfully isolated from hind limb muscle;
2) PICs can be propagated in culture for long periods
whilst maintaining a stable phenotype; 3) PICs are clo-
nogenic and self-renewing in vitro; 4) PICs express
markers of pluripotency; 5) PICs display multipotent dif-
ferentiation potential expressing proteins and transcripts
from cells of the three germ layers in vitro and in vivo;
6) clonal PICs are primarily driven towards a mesoder-
mal and specifically skeletal muscle lineage; and 7) PICs
are not tumorigenic.
Although the number of PICs decreases with age
(Additional file 4: Figure S1), there are still adequate
numbers into young adulthood to efficiently isolate
enough PICs for their propagation in a defined stem/
progenitor cell growth culture media. This study is the
first to show that murine PICs can be propagated and
maintained in long-term culture. The media used is one
optimised by our group and has previously been used to
culture porcine PICs (pPICs) [18] and cardiac stem/pro-
genitor cells [29, 31]. Indeed, we previously demon-
strated pPICs were capable of maintaining a stable
phenotype and karyotype over 40 passages [18]. The im-
portance of using the correct growth media was further
reinforced in this study by the growth senescence of
PICs when placed in promocell growth media (Fig. 1).
Clonal PIC cell lines displayed a similar morphology
and phenotype to both bulk PICs and each other, as did
their sub-clonal counterparts. A clonal population was
chosen for assessment over time in culture to ensure
that results were characteristic of PICs and were not an
artefact of a mixed cell population. C9 was subsequently
chosen for further analysis due to it being the most simi-
lar to the transcription profile of non-cloned ‘bulk’ cells,
and the phenotype of PICs in general. The ability to
propagate PICs in vitro is in contrast to that seen in sat-
ellite cells which rapidly lose their self-renewal proper-
ties and undergo differentiation [32]. These data favour
the use of PICs over satellite cells for expansion and
their use in cell regenerative therapeutic settings.
When propagated in culture, PICs displayed character-
istics of stem cells, being clonogenic and self-renewing.
PICs demonstrated an ability to form single cell-derived
clonal populations; their clonal efficiency of ~34% was
less than reported in pPICS (53%) [18], but is within the
range previously reported for other adult stem/progeni-
tor cell populations, such as porcine skin stem cells [33].
Moreover, C9 PICs retained a subsequent clonogenicity
of ~91%, substantiating their clonogenic properties, and
self-renewal ability. This is the first study to propagate
and compare clones, and subsequently sub-clone PICs.
C9 PICs exhibited a stable population doubling (PD)
over 20 passages, demonstrating that each generation is
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Fig. 6 PICs show multi-potent potential in vitro and in vivo. a–h Representative confocal micrographs of C9 PICs following directed differentiation
into endothelial (a), hepatic (b,c) and neuronal (e–h) lineages. d Flow cytometric analysis of C9 PICs for albumin expression after 14 days of hepatic
differentiation. i Immunohistochemical staining of teratomas from PIC/ESC-treated mice showing GFP+ cells expressing markers of the three germ
layers. Arrows indicate co-staining of green fluorescent protein (GFP) with αFP (endoderm), β3-tubulin (ectoderm), desmin, and smooth muscle actin
(SMA) (mesoderm). Scale bars = 50 μm in all micrographs. ChAT choline acetyltransferase, CK cytokeratin, ENO2 gamma-enolase, GFAP glial fibrillary
acidic protein, vWF von Willebrand factor
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as proliferative as its predecessor. A shorter PD is indi-
cative of a higher rate of proliferation: the PD of murine
ESCs is ~10–14 h [34], porcine iPSCs derived from fetal
fibroblasts have a PD of ~17 h [35], whilst pPICS have a
PD of ~22 h [18]. The doubling time of PICs isolated
from the mouse (~16 h) was shorter than that reported
in pPICs, which could be because murine PICs are more
proliferative than pPICs or the pPIC population was not
a clonal cell line and was not sorted for Sca-1, and was
therefore heterogeneous. In heterogeneous populations,
different cell types divide at different rates, therefore af-
fecting the overall doubling time. In contrast, C9 PICs
were derived from a single cell and thus all cells should
display a similar rate of proliferation.
The total number of population doublings over 20 pas-
sages was calculated to be ~64, far surpassing Hayflick’s
limit of 14–28 doublings for cells of murine origin, as well
as also extending beyond the 40–60 doublings initially re-
ported as the maximum in human cells [36]. Importantly,
in addition to maintaining their PD, C9 PICs also retained
their morphology and phenotype over time in culture, dis-
playing comparable levels of PW1 and Sca-1 at P2 and P20.
This is the first study to describe the presence of pluri-
potency markers in murine PICs. As expected, the levels
of pluripotency gene transcripts were lower in PICs than
in ESCs, although they were still substantial. It was
noted that there was a decrease in transcript levels of all
three pluripotency genes over time in culture in clonal
and sub-clonal PICs. Whether the pluripotent potential
of the cells differed with time was not tested. Despite
these discrepancies, the growth kinetics and morphology
did not change. This therefore suggests they could be ar-
tefacts of the in vitro environment rather than an inabil-
ity of the PICs to self-renew competently. In vivo PICs
would naturally inhabit a three-dimensional environ-
ment interacting with many other cell types and in vitro
conditions cannot currently provide an identical niche to
that in which they naturally reside within the tissue of
origin. Bulk PICs had the highest number of transcripts
for pluripotency markers; however, bulk PICs were not
cultured long term. Therefore, it is not known if PICs
self-renew more efficiently in a heterogeneous culture.
This study demonstrates that a single PIC is capable of
generating both types of muscle—striated and smooth.
This may also account for the difference in ratio with
the clonal cell line used displaying an affinity towards
skeletal muscle, whilst the previously described hetero-
geneous populations harbour cells that form both types
[17, 18, 20]. Aside from the differences in ratio, all stud-
ies are in agreement that PICs are capable of forming
both skeletal and smooth muscle. Importantly, the ob-
servation of twitching fibres at 5 days of differentiation
indicates functionality of the muscle fibres and not just
phenotypic and biochemical expression.
In the present study, clonal PICs expressed low
PDGFRα, whereas the PICs reported by Lewis et al. [18]
and Pannérec et al. [20] expressed PDGFRα. The expres-
sion of PDGFRα could determine the differentiation cap-
acity of PICs into either skeletal or smooth muscle [17,
20]. Indeed, Pannérec et al. [20] reported that PDGFRα-
positive PICs were capable of adipogenic differentiation
but did not display myogenic differentiation potential,
whilst PDGFRα-negative PICs had myogenic potential
but lacked adipogenic differentiation capability. Further-
more, these findings are in agreement with previous data
that PDGFRα+ cells in adult muscle interstitium are
fibro-adipogenic progenitor (FAP) cells [16, 37]. With
regard to skeletal and smooth muscle differentiation, the
present study is the first to show the direct endothelial
cell differentiation potential of PICs. However, full differ-
entiation and functional maturity was not tested.
For the first time, this study demonstrated that PICs
can cross the germ layer barrier and contribute to the
formation of cell types from all three lineages in vitro
and in vivo. However, whilst these assays suggest a broad
differentiation potential with upregulation of lineage
specific markers for all three germ layers, they do not
demonstrate any functionality of PIC-derived differenti-
ated cells. In both differentiation assays PICs showed a
greater affinity towards the mesodermal lineage, with
higher transcript levels and fold changes in vitro, and
more PICs co-expressing mesodermal proteins, than
endodermal or ectodermal ones in vivo. Furthermore, in
vitro differentiation resulted in immature cells suggesting
that either PICs are not capable of full differentiation due
to intrinsic processes, or more efficient differentiation
conditions (i.e. three-dimensional environment, scaffolds)
are needed to drive full maturation.
The ability to cross the germ-layer barrier is rare but
not unknown in adult stem cell populations. In 2007,
Beltrami et al. demonstrated that Oct3/4+/Nanog+/REX1
+ human multipotent adult stem cells (hMASCs), iso-
lated from the liver, heart, and bone marrow, were
capable of cross-lineage differentiation in vitro, each
demonstrating differentiation into neuron (ectoderm)-,
osteoblast (mesoderm)-, and hepatocyte (endoderm)-like
cells [38]. Similarly, murine PDGFRα+ cardiac resident
cCFU cells are capable of hepatic, endoderm, and neur-
onal differentiation in vitro. Furthermore, when GFP-
labelled cCFUs cells were transplanted alongside un-
labelled ESCs under the kidney capsule of a mouse,
resulting teratomas contained GFP-expressing cells from
all three germ layer lineages [39]. Moreover, muscle-
derived stem cells, obtained via pre-plating, have previ-
ously been shown to differentiate into hepatocyte-like
cells when co-cultured with hepatocytes, expressing al-
bumin and HNF1α [40]. When injected into liver tissue
following partial hepatectomy, they engraft and persist
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>3 months post-transplantation [40]. The functionality
of cells generated in vitro is hard to determine, and be-
haviour in vitro does not necessarily encapsulate the
behaviour of their in vivo counterparts. Importantly, Dil-
labelled adult neural stem cells have shown transdermal
differentiation, contributing to the formation of chimeric
chick and mouse embryos, and to cell formation of all
three germ layers [41]. This suggests that some adult
stem cell populations are capable of generating func-
tional cells of multiple lineages.
PICs did not form teratomas in vivo, suggesting they
have multipotent potential, but are not pluripotent, as
also seen in PDGFRα+ cardiac cCFUs cells [39]. Im-
portantly, the inability of PICs to form teratomas inde-
pendently means they are good cell candidates for
cellular therapies. It is yet to be tested whether their
pluripotent capability would have any unwanted con-
sequences in tissue-specific regeneration, however pre-
vious studies using PICs to regenerate damaged
skeletal muscle in both mice and pigs have not re-
ported any [17, 18].
Whilst PICs have previously been shown to contribute
to the formation of new smooth and skeletal muscle
upon acute injury [17, 18], it has not yet been deter-
mined if they are suitable and effective for treating
chronic conditions such as muscular dystrophy. There-
fore, the next step is to elucidate the therapeutic poten-
tial of PICs using the mdx mouse model. Furthermore,
the bi-potent differentiation potential of PICs makes
them an ideal cell candidate to engineer skeletal muscle
tissue constructs in vitro. A difficulty of generating skel-
etal muscle tissue constructs in vitro is the formation of
perfusable blood vessels within the tissue construct.
PICs, when stimulated under the right cues, would be
able to differentiate into either smooth muscle or stri-
ated skeletal muscle. It has been shown that co-culture
of C2C12 myoblasts, embryonic fibroblasts, and endo-
thelial cells on highly porous and biodegradable polymer
scaffolds resulted in the formation of endothelial net-
works within engineered muscle tissues in vitro and en-
hanced vascularization, blood perfusion, and survival of
the tissue constructs after implantation [42]. Electrical
stimulation and force production are also important
cues for skeletal muscle development and maturation.
Therefore, the ability of PICs (in co-culture with endo-
thelial cells) to engineer skeletal muscle in vitro should
be tested using biocompatible hydrogels/scaffolds to-
gether with the use of electrical pulse stimulation [43] to
recapitulate the in vivo niche.
Conclusion
In conclusion, murine PICs display properties of bona
fide tissue-specific stem/progenitor cells, being clono-
genic, self-renewing, and multipotent in vitro and in
vivo. However, clonal PICs display a strong preference
towards the skeletal muscle lineage from which they ori-
ginate. Furthermore, PICs are not tumorigenic. These
data validate the ability of isolated PICs to undergo in
vitro propagation with the prospect of generating large
numbers of these cells to be used in cellular regenerative
therapies to treat a variety of diseases.
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staining (F). Scale bar = 100 μm. (PDF 713 kb)
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